- Home
- SLXN vs POAI Comparison
SLXN vs POAI Comparison
Compare SLXN & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- POAI
- Stock Information
- Founded
- SLXN 2008
- POAI 2002
- Country
- SLXN Israel
- POAI United States
- Employees
- SLXN N/A
- POAI N/A
- Industry
- SLXN
- POAI Industrial Specialties
- Sector
- SLXN
- POAI Health Care
- Exchange
- SLXN NYSE
- POAI Nasdaq
- Market Cap
- SLXN 5.2M
- POAI 4.9M
- IPO Year
- SLXN N/A
- POAI N/A
- Fundamental
- Price
- SLXN $2.44
- POAI $0.69
- Analyst Decision
- SLXN Strong Buy
- POAI Hold
- Analyst Count
- SLXN 1
- POAI 1
- Target Price
- SLXN $1.00
- POAI N/A
- AVG Volume (30 Days)
- SLXN 1.3M
- POAI 93.1K
- Earning Date
- SLXN 11-14-2024
- POAI 11-12-2024
- Dividend Yield
- SLXN N/A
- POAI N/A
- EPS Growth
- SLXN N/A
- POAI N/A
- EPS
- SLXN N/A
- POAI N/A
- Revenue
- SLXN N/A
- POAI $1,484,223.00
- Revenue This Year
- SLXN N/A
- POAI N/A
- Revenue Next Year
- SLXN N/A
- POAI $569.48
- P/E Ratio
- SLXN N/A
- POAI N/A
- Revenue Growth
- SLXN N/A
- POAI N/A
- 52 Week Low
- SLXN $0.21
- POAI $0.55
- 52 Week High
- SLXN $13.56
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- POAI 40.72
- Support Level
- SLXN N/A
- POAI $0.69
- Resistance Level
- SLXN N/A
- POAI $0.76
- Average True Range (ATR)
- SLXN 0.00
- POAI 0.06
- MACD
- SLXN 0.00
- POAI -0.01
- Stochastic Oscillator
- SLXN 0.00
- POAI 4.80
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.